HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

INBX

Inhibrx Biosciences Inc

Last Close
Mar 21 • 04:00PM ET
14.35
Dollar change
+0.25
Percentage change
1.77 		%
Healthcare • Biotechnology • USA • NASD
Peers: BPMC ARVN ONC PTCT EXEL PBYI ADAP KPTI IGMS
 | Held by: VTI IWM VXF IBB IWO VTWO IWN IWC FESM EES
Scroll to Statements
IndexRUT P/E0.12 EPS (ttm)116.58 Insider Own31.28% Shs Outstand14.48M Perf Week1.77%
Market Cap207.73M Forward P/E- EPS next Y-7.63 Insider Trans2.42% Shs Float9.95M Perf Month12.11%
Income1.69B PEG- EPS next Q-2.83 Inst Own65.75% Short Float11.92% Perf Quarter-1.37%
Sales0.20M P/S1038.65 EPS this Y-110.29% Inst Trans18.04% Short Ratio13.56 Perf Half Y-15.54%
Book/sh9.23 P/B1.56 EPS next Y34.17% ROA- Short Interest1.19M Perf Year-
Cash/sh10.54 P/C1.36 EPS next 5Y- ROE- 52W Range10.80 - 18.95 Perf YTD-6.82%
Dividend Est.- P/FCF- EPS past 5Y- ROI1205.09% 52W High-24.27% Beta-
Dividend TTM- Quick Ratio3.94 Sales past 5Y-53.39% Gross Margin-1042.00% 52W Low32.87% ATR (14)0.83
Dividend Ex-Date- Current Ratio3.94 EPS Y/Y TTM- Oper. Margin-165724.00% RSI (14)59.84 Volatility4.80% 6.86%
Employees161 Debt/Eq0.06 Sales Y/Y TTM- Profit Margin843786.00% Recom3.00 Target Price15.00
Option/ShortYes / Yes LT Debt/Eq0.05 EPS Q/Q-1.73% Payout0.00% Rel Volume1.35 Prev Close14.10
Sales Surprise- EPS Surprise-7.11% Sales Q/Q233.33% EarningsMar 17 AMC Avg Volume87.49K Price14.35
SMA205.88% SMA507.77% SMA200-0.49% Trades Volume118,160 Change1.77%
Date Action Analyst Rating Change Price Target Change
Jul-23-24Initiated JMP Securities Mkt Perform
Mar-17-25 04:05PM
Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results
(PR Newswire)
Jan-21-25 05:01PM
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer
(PR Newswire) +5.19%
Jan-13-25 04:15PM
Inhibrx Biosciences Announces Loan Agreement with Oxford Finance
(PR Newswire) -6.60%
Nov-14-24 04:24PM
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results
(PR Newswire) -7.25%
Nov-04-24 04:00PM
Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation
(PR Newswire)
01:55AM Loading…
Sep-13-24 01:55AM
Director Kristiina Vuori Purchases Shares of Inhibrx Biosciences Inc (INBX)
(GuruFocus.com) +8.82%
Aug-13-24 06:54PM
Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
(PR Newswire)
May-24-24 04:00PM
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi
(PR Newswire)
May-10-24 06:36PM
Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off
(PR Newswire)
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded on January 8, 2024 and is headquartered in La Jolla, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kayyem Jon FaizDirectorNov 19 '24Buy14.2369,686991,41651,093Nov 22 04:03 PM
Kayyem Jon FaizDirectorNov 20 '24Buy14.1937,500532,20469,843Nov 22 04:03 PM
Lappe MarkChief Executive OfficerSep 12 '24Buy15.0526,963405,793692,511Sep 16 05:12 PM
Lappe MarkChief Executive OfficerSep 16 '24Buy17.1313,037223,324705,548Sep 16 05:12 PM
Vuori Kristiina MDDirectorSep 11 '24Buy15.076,45797,30713,776Sep 12 05:14 PM
Vuori Kristiina MDDirectorSep 10 '24Buy15.001792,6857,319Sep 12 05:14 PM
Lappe MarkChief Executive OfficerSep 06 '24Buy15.2926,000397,540647,548Sep 10 05:00 PM
Lappe MarkChief Executive OfficerSep 09 '24Buy15.219,500144,495657,048Sep 10 05:00 PM
Lappe MarkChief Executive OfficerSep 10 '24Buy15.198,500129,115665,548Sep 10 05:00 PM
Lappe MarkChief Executive OfficerSep 03 '24Buy15.8120,000316,263165,000Sep 03 05:31 PM
Lappe MarkChief Executive OfficerAug 29 '24Buy14.0310,000140,300135,000Sep 03 05:31 PM
Lappe MarkChief Executive OfficerAug 30 '24Buy14.0210,000140,200145,000Sep 03 05:31 PM
Vuori Kristiina MDDirectorAug 29 '24Buy14.007,14099,9607,140Sep 03 04:27 PM
MANHARD KIMBERLYDirectorAug 28 '24Buy13.9810,000139,80010,000Aug 30 04:16 PM
FORSYTH DOUGLASDirectorAug 23 '24Buy14.0759,812841,555224,564Aug 26 04:26 PM
FORSYTH DOUGLASDirectorAug 22 '24Buy12.8915,188195,773164,752Aug 26 04:26 PM
Lappe MarkChief Executive OfficerAug 20 '24Buy12.9727,055350,90341,920Aug 22 04:29 PM
Lappe MarkChief Executive OfficerAug 21 '24Buy12.9312,945167,37954,865Aug 22 04:29 PM
Kayyem Jon FaizDirectorJun 05 '24Buy17.3257,549997,0241,150,410Jun 07 06:05 PM
Eckelman Brendan P.Chief Scientific OfficerMay 28 '24Sale34.30300,00010,290,0001,735,553May 30 06:21 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.